Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Neuronetics (STIM) Long-Term Debt Issuances (2020 - 2024)

Neuronetics (STIM) reported Long-Term Debt Issuances of $9.4 million for Q4 2024, down 58.24% year-over-year from $22.5 million in Q1 2024, and down 58.24% on a QoQ basis from $22.5 million in Q4 2023.

Neuronetics (STIM) has 3 years of Long-Term Debt Issuances data on file, last reported at $9.4 million in Q4 2024.

  • Quarterly Long-Term Debt Issuances fell 58.24% year-over-year to $9.4 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $31.9 million (changed 0.0% YoY) and the FY2025 annual result came in at $10.0 million, down 82.6% from the prior year.
  • Long-Term Debt Issuances fell to $9.4 million in Q4 2024 per STIM's latest filing, from $22.5 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $35.0 million in Q1 2020 and bottomed at $2.5 million in Q1 2023.
  • The 3-year median for Long-Term Debt Issuances is $9.4 million (2024), against an average of $15.2 million.
  • Peak annual rise in Long-Term Debt Issuances reached 58.24% in 2024, while the deepest fall reached 58.24% in 2024.
  • Tracing STIM's Long-Term Debt Issuances over 3 years: stood at $6.4 million in 2020, then soared by 253.77% to $22.5 million in 2023, then tumbled by 58.24% to $9.4 million in 2024.
  • Per Business Quant, the three latest STIM Long-Term Debt Issuances figures stand at $9.4 million (Q4 2024), $22.5 million (Q4 2023), and $2.5 million (Q1 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 19.86 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 11.71 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 1.15 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Neuronetics 3.26 Mn -6.42 Mn 16.15 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 9.40 Mn
Dec 31, 2024 9.40 Mn
Dec 31, 2023 22.50 Mn
Dec 31, 2023 22.50 Mn
Mar 31, 2023 2.50 Mn
Mar 31, 2023 2.50 Mn
Jun 30, 2020 6.36 Mn
Jun 30, 2020 6.36 Mn
Mar 31, 2020 35.00 Mn
Mar 31, 2020 35.00 Mn